Aktis Oncology Inc
aktisoncology.comWhat Do They Do?
Develops miniprotein-based radioactive drug candidates for cancer patients, designed to deliver radiation to targeted solid tumors.
10-K, filed Mar 30, 2026We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient…View ↗
We have built a proprietary miniprotein radioconjugate platform that aims to safely confer breakthrough efficacy to a broad range of…View ↗
Our platform capabilities have generated a pipeline of several novel product candidates. Our most advanced program is a radiopharmaceutical…View ↗
Who Are Their Customers?
Aktis works directly with Eli Lilly under a research and collaboration agreement that includes a license to Aktis intellectual property and research and development services.
10-K, filed Mar 30, 2026
How Are They Changing?
Who Do They Compete With?
Competes with Abdera Therapeutics, Actinium Pharmaceuticals, Alpha9 Oncology, Artbio, Bayer, Convergent Therapeutics, Fusion Pharmaceuticals, Johnson & Johnson, Mariana Oncology, Perspective Therapeutics, POINT Biopharma Global, RadioMedix, Radionetics Oncology, RayzeBio, and Telix Pharmaceuticals
10-K, filed Mar 30, 2026We consider our most direct competitors to be companies developing targeted alpha-based radiopharmaceuticals for the treatment of cancer.…View ↗
Loading...
